Home  /  Resource Library  /  The ECHELON-2 Trial: 5 year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

The ECHELON-2 Trial: 5 year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Long term results of a study investigating brentuximab Vedotin combined with chemotherapy for treatment of peripheral T-cell lymphomas